Galmed Pharmaceuticals Ltd (GLMD) FinancialsGLMDFinancialGalmed Pharmaceuticals Ltd

Evaluating the bottom line, Galmed Pharmaceuticals Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -72.12%, provide a clear picture of how effectively GLMD converts its operational activities into shareholder value.

In the context of the broader market, GLMD competes directly with industry leaders such as SBFM and JAGX. With a market capitalization of $4.48M, it holds a significant position in the sector. When comparing efficiency, GLMD's gross margin of N/A stands against SBFM's 25.35% and JAGX's 15.84%. Such benchmarking helps identify whether Galmed Pharmaceuticals Ltd is trading at a premium or discount relative to its financial performance.

Galmed has consistently reported negative net income, with the latest figure for Q1 2026 being -1,910,000 USD. The company also has a negative price-to-earnings ratio of -0.33 and a forward P/E of 0, indicating a lack of profitability and future earnings potential.